Shout out to CroíValve for featuring in CM Medical‘s article this week!
The article looks at life-saving heart innovations that have emerged over the last 20 years while exploring the life-changing breakthrough device CroíValve developed, the Duo Coaptation Valve.
A solution for tricuspid valve regurgitation has been much more elusive, despite the problem being more widespread. Tricuspid regurgitation (TR) is a severe heart condition that occurs when the tricuspid valve fails to seal properly, allowing blood to flow retrograde from the right ventricle into the right atrium. This is an issue affecting over half-a-million people every year in the US and EU alone, which until recently there was no suitable solution.
CroíValve is an early stage medical device company focused on developing a minimally invasive device for the treatment of tricuspid regurgitation. It is based in Dublin, Ireland, and combines significant clinical, technical and commercial experience.
The CroíValve device, the Duo Coaptation Valve, is used to restore tricuspid valve function atraumatically. The unique, atraumatic approach of the Duo device allows for temporary implantation of the device to restore function without any impact to the native anatomy.
In March, CroíValve announced the first successful human use of their device with the surgery performed at St James’ University Hospital in Dublin.
Check out the article here for more information on CroíValve’s incredible achievements.